Market closed
C4 Therapeutics/$CCCC
C4 Therapeutics shares are trading lower after the company reported a Q1 loss, despite exceeding revenue estimates.
22 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About C4 Therapeutics
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
Ticker
$CCCC
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
110
ISIN
US12529R1077
Website
C4 Therapeutics Metrics
BasicAdvanced
$109M
-
-$1.48
3.11
-
Price and volume
Market cap
$109M
Beta
3.11
52-week high
$7.66
52-week low
$1.09
Average daily volume
1.2M
Financial strength
Current ratio
5.697
Quick ratio
5.466
Long term debt to equity
29.951
Total debt to equity
32.985
Management effectiveness
Return on assets (TTM)
-20.30%
Return on equity (TTM)
-45.55%
Valuation
Price to revenue (TTM)
2.709
Price to book
0.56
Price to tangible book (TTM)
0.56
Price to free cash flow (TTM)
-1.339
Growth
Revenue change (TTM)
98.56%
Earnings per share change (TTM)
-36.21%
3-year revenue growth (CAGR)
-4.73%
3-year earnings per share growth (CAGR)
-9.53%
What the Analysts think about C4 Therapeutics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for C4 Therapeutics stock.
C4 Therapeutics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
C4 Therapeutics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
C4 Therapeutics News
AllArticlesVideos
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewsWire·3 days ago
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
GlobeNewsWire·2 months ago
C4 Therapeutics to Participate in Upcoming March Investor Conferences
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for C4 Therapeutics stock?
C4 Therapeutics (CCCC) has a market cap of $109M as of May 10, 2025.
What is the P/E ratio for C4 Therapeutics stock?
The price to earnings (P/E) ratio for C4 Therapeutics (CCCC) stock is 0 as of May 10, 2025.
Does C4 Therapeutics stock pay dividends?
No, C4 Therapeutics (CCCC) stock does not pay dividends to its shareholders as of May 10, 2025.
When is the next C4 Therapeutics dividend payment date?
C4 Therapeutics (CCCC) stock does not pay dividends to its shareholders.
What is the beta indicator for C4 Therapeutics?
C4 Therapeutics (CCCC) has a beta rating of 3.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.